Dyne Therapeutics (DYN) said late Tuesday it priced an upsized underwritten public offering of 19 million shares at $18.44 per share for gross proceeds of about $350 million.
The offering is expected to close on Thursday.
In addition, Dyne said it has granted the underwriters a 30-day option to purchase up to an additional 2.8 million shares.